Stemline Therapeutics (NASDAQ:STML) Stock Price Up 5.1%

Stemline Therapeutics Inc (NASDAQ:STML) shares were up 5.1% during trading on Friday . The stock traded as high as $10.39 and last traded at $10.32, approximately 547,906 shares traded hands during mid-day trading. A decline of 11% from the average daily volume of 615,361 shares. The stock had previously closed at $9.81.

STML has been the subject of a number of recent analyst reports. ValuEngine cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 11th. Zacks Investment Research lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stemline Therapeutics in a research note on Monday, November 11th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Stemline Therapeutics currently has an average rating of “Buy” and an average price target of $22.57.

The stock’s 50-day moving average price is $10.04 and its 200-day moving average price is $12.30.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The company had revenue of $13.33 million during the quarter, compared to analyst estimates of $13.40 million. On average, equities research analysts expect that Stemline Therapeutics Inc will post -1.77 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of STML. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Stemline Therapeutics by 51.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,466 shares during the period. Bank of Montreal Can acquired a new position in shares of Stemline Therapeutics during the second quarter valued at $52,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Stemline Therapeutics during the second quarter valued at $67,000. Tower Research Capital LLC TRC boosted its holdings in Stemline Therapeutics by 364.4% in the third quarter. Tower Research Capital LLC TRC now owns 7,115 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 5,583 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Stemline Therapeutics in the second quarter valued at about $104,000. 83.07% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

See Also: Earnings Per Share

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit